Tissue Binding
Tissue Binding - Related Videos
01:21
Drug Distribution: Tissue Binding
0 Views •
2023
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity. For...
08:40
Methyl-binding DNA capture Sequencing for Patient Tissues
0 Views •
Cited by 1 •
2016
Here we present a protocol to investigate genome wide DNA methylation in large scale clinical patient screening studies using the Methyl-Binding DNA Capture sequencing (MBDCap-seq or MBD-seq) technology and the subsequent bioinformatics analysis pipeline.
01:24
Tissue-Drug Binding: Localization of Drugs and its Significance
0 Views •
2025
Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules. Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine the...
02:18
The Equilibrium Binding Constant and Binding Strength
0 Views •
2020
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium: where P and L are the unbound protein and ligand, respectively, and PL is the protein-ligand complex. As the amount of bound ligand is also related to the rate of ligand binding, experiments can also determine Kb by examining the rates of protein-ligand association (kon) and dissociation (koff) using the following ratio: Thus,...
07:53
Actin Co-Sedimentation Assay; for the Analysis of Protein Binding to F-Actin
0 Views •
Cited by 18 •
2008
Proteins bind to filamentous actin (F-actin) through distinct actin binding modules. In this video we demonstrate the procedure of actin co-sedimentation, which is an in vitro assay routinely used to analyze proteins or specific domains that bind F-actin.
FAQs
Three features work together: a compound’s physicochemical properties, the composition of the target tissue, and local blood flow. These factors influence whether molecules enter tissue readily, partition into tissue lipids, or associate with proteins, nucleic acids, or extracellular matrix components. Considering all three helps explain why distribution can vary among tissues and among drugs.
Because the association is reversible, tissue-held molecules can remain available as a reservoir rather than representing permanent sequestration. Such retention can contribute to a longer duration of action and affect how long a compound persists in the body. The resulting distribution pattern also helps account for an apparent volume of distribution that extends beyond circulating fluid.
Circulating concentration reflects drug present in the bloodstream, whereas total concentration can also include drug associated with tissues. A strong tissue contribution may therefore make these values diverge. In clinical pharmacology, distinguishing them is important when interpreting pharmacokinetic measurements, because blood measurements alone may not fully represent the amount distributed throughout the body.
Partitioning into lipids and noncovalent association with tissue macromolecules are distinct ways a compound can be retained. Proteins, nucleic acids, and extracellular matrix components support molecular association, while tissue lipids provide a partitioning environment. Which pathway predominates depends on both the molecule and the tissue, so different compounds can show different distribution and persistence patterns.
Measuring or modeling tissue binding gives pharmacokinetic analyses a way to account for drug associated with tissues rather than relying only on circulating concentrations. This information helps interpret apparent volume of distribution and persistence, improving assessment of how a compound behaves after distribution. It therefore supports more informed dose selection and evaluation of observed pharmacokinetic profiles.
In clinical pharmacology, the information is useful when dose selection, efficacy, persistence, toxicity, or potential drug interactions must be assessed together. Tissue association can alter how long a compound remains present and how tissue and circulating concentrations relate. Incorporating that context helps researchers interpret treatment effects and safety concerns without treating blood concentration as the complete picture.